At the news
? NEUTRALIMPACT 3/10 CLUSTER filed Mar 4, 2026 at 19:00 ET
Two top executives at Dyne Therapeutics, the CEO and Chief Medical Officer, sold shares in a coordinated open-market transaction totaling approximately $54,200. The sales represent a routine divestiture with minimal dollar value relative to the company's $2.5B market cap.
- CEO John Cox sold 2,732 shares for $40,706.80 in an open-market transaction.
- Chief Medical Officer Douglas Kerr sold 904 shares for $13,469.60, also via open-market sale.
- Total value of insider sales: $54,176.40 across two C-suite executives.
- Sales occurred on the same day at $14.90 per share, within normal trading activity.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access